IT1262896B
(it)
*
|
1992-03-06 |
1996-07-22 |
|
Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
|
US5849301A
(en)
*
|
1993-09-22 |
1998-12-15 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
|
NZ274376A
(en)
*
|
1993-09-22 |
1997-11-24 |
Jackson H M Found Military Med |
Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
|
AU712981B2
(en)
*
|
1995-03-22 |
1999-11-18 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
|
NZ306316A
(en)
*
|
1995-04-17 |
2001-06-29 |
Smithkline Beecham Biolog S |
use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen
|
US20030157129A1
(en)
*
|
1995-06-23 |
2003-08-21 |
Smithkline Beecham Biologicals S.A. |
Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
|
AU2429397A
(en)
*
|
1996-03-29 |
1997-10-22 |
David S. Terman |
Polymerized staphylococcal protein a for treatment of diseases
|
US6309646B1
(en)
|
1996-05-09 |
2001-10-30 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
|
DK0912195T3
(da)
|
1996-06-25 |
2009-05-18 |
Pepscan Systems Bv |
Vaccine indeholdende antigener bundet til bærestoffer gennem labile bindinger
|
US6248334B1
(en)
|
1997-01-08 |
2001-06-19 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
|
US6299881B1
(en)
*
|
1997-03-24 |
2001-10-09 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
|
DE69826851T2
(de)
*
|
1997-04-24 |
2005-02-10 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
|
US5929049A
(en)
*
|
1997-08-08 |
1999-07-27 |
Dade Behring Marburg Gmbh |
Polysaccharide conjugates of biomolecules
|
US6284250B1
(en)
*
|
1998-02-05 |
2001-09-04 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
|
AU3005499A
(en)
*
|
1998-03-16 |
1999-10-11 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Induction and enhancement of the immune response to type-2 cell-independent antigens conjugated to lipid or lipid-containing moieties
|
EP1069909B1
(en)
*
|
1998-04-10 |
2007-06-13 |
Andrew Lees |
Conjugate vaccines for the prevention of dental caries
|
GB9808932D0
(en)
*
|
1998-04-27 |
1998-06-24 |
Chiron Spa |
Polyepitope carrier protein
|
WO1999064603A2
(en)
*
|
1998-06-12 |
1999-12-16 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV Gp350/220
|
CA2338093C
(en)
*
|
1998-07-20 |
2010-11-30 |
Shousun C. Szu |
Vaccines against escherichia coli o157 infection
|
US6858211B1
(en)
*
|
1998-07-20 |
2005-02-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccines against Escherichia coli O157 infection
|
US6585973B1
(en)
|
1998-10-29 |
2003-07-01 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Method for preparing solid phase conjugated vaccine
|
US6797275B1
(en)
*
|
1998-12-04 |
2004-09-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
|
GB9909077D0
(en)
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
DE60038166T2
(de)
|
1999-03-19 |
2009-03-12 |
Glaxosmithkline Biologicals S.A., Rixensart |
Impfstoff gegen bakterielle antigene
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
PE20020126A1
(es)
|
2000-06-29 |
2002-04-27 |
Smithkline Beecham Biolog |
Composicion de vacuna
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US7534442B2
(en)
*
|
2001-08-21 |
2009-05-19 |
The Brigham And Women's Hospital, Inc. |
Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
|
AU2003257003A1
(en)
*
|
2002-07-30 |
2004-02-16 |
Baxter Healthcare S.A. |
Chimeric multivalent polysaccharide conjugate vaccines
|
DE60335477D1
(de)
|
2002-10-11 |
2011-02-03 |
Novartis Vaccines & Diagnostic |
Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
DK1587537T3
(da)
|
2003-01-30 |
2012-07-16 |
Novartis Ag |
Injicerbare vacciner mod multiple meningococ-serogrupper
|
CN1787839B
(zh)
*
|
2003-03-07 |
2011-09-28 |
惠氏控股公司 |
用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
|
CA2540896C
(en)
|
2003-10-02 |
2015-06-02 |
Chiron Srl |
Liquid vaccines for multiple meningococcal serogroups
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
AU2005209303A1
(en)
*
|
2004-01-29 |
2005-08-11 |
Biosynexus, Inc. |
Use of amino-oxy functional groups in the preparation of vaccines conjugates
|
DK1740217T3
(da)
|
2004-04-30 |
2011-09-26 |
Novartis Ag |
Meningokok-konjugat-vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
US7456000B2
(en)
*
|
2004-08-26 |
2008-11-25 |
Siemens Healthcare Diagnostics Inc. |
Deactivation of linking moieties in antibody-enzyme conjugates
|
BRPI0515520A
(pt)
|
2004-09-22 |
2008-07-29 |
Glaxosmithkline Biolog Sa |
composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
|
GB0505518D0
(en)
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
SI1868645T1
(sl)
|
2005-04-08 |
2012-04-30 |
Wyeth Llc |
Večvalentni pnevmokokni sestavek konjugata polisaharid-protein
|
CA2611960C
(en)
|
2005-06-27 |
2015-05-05 |
Glaxosmithkline Biologicals S.A. |
Immunogenic compositions comprising n.meningitidis capsular saccharide conjugates
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
AR058592A1
(es)
|
2005-12-22 |
2008-02-13 |
Glaxosmithkline Biolog Sa |
Vacuna
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP1993604B1
(en)
|
2006-03-17 |
2015-12-02 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Methods for preparing complex multivalent immunogenic conjugates
|
AU2007229449A1
(en)
|
2006-03-22 |
2007-10-04 |
Novartis Ag |
Regimens for immunisation with meningococcal conjugates
|
EA015833B1
(ru)
|
2006-03-30 |
2011-12-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Иммуногенная композиция
|
AU2007293673B2
(en)
|
2006-09-07 |
2013-06-27 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
PE20090212A1
(es)
|
2007-05-02 |
2009-03-30 |
Glaxosmithkline Biolog Sa |
Kit de vacuna para la inmunizacion primaria
|
JP2010531330A
(ja)
|
2007-06-26 |
2010-09-24 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
肺炎連鎖球菌莢膜多糖コンジュゲートを含むワクチン
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
EP2772267B1
(en)
|
2007-08-27 |
2016-04-27 |
Longhorn Vaccines and Diagnostics, LLC |
Immunogenic compositions and methods
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ587382A
(en)
|
2008-02-21 |
2012-01-12 |
Novartis Ag |
Meningococcal fhbp polypeptides
|
AU2009302582A1
(en)
|
2008-10-06 |
2010-04-15 |
University Of Chicago |
Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
HUE026855T2
(en)
|
2009-04-03 |
2016-07-28 |
Univ Chicago |
Preparations and method for Protein A (SPA) variants
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
WO2010141312A2
(en)
|
2009-06-01 |
2010-12-09 |
Wake Forest University Health Sciences |
Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
|
US9125951B2
(en)
|
2009-06-22 |
2015-09-08 |
Wyeth Llc |
Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
|
PT2445522T
(pt)
|
2009-06-22 |
2017-10-04 |
Wyeth Llc |
Composições imunogénicas de antigénios de staphylococcus aureus
|
US8647621B2
(en)
|
2009-07-27 |
2014-02-11 |
Fina Biosolutions, Llc |
Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
NZ598458A
(en)
|
2009-08-27 |
2014-03-28 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
WO2011036560A2
(en)
|
2009-09-23 |
2011-03-31 |
Novartis Ag |
Glycoconjugate compositions and methods for treatment of hiv
|
AU2010302344A1
(en)
|
2009-09-30 |
2012-04-26 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
GB0917647D0
(en)
|
2009-10-08 |
2009-11-25 |
Glaxosmithkline Biolog Sa |
Expression system
|
JP5960055B2
(ja)
|
2009-10-27 |
2016-08-02 |
ノバルティス アーゲー |
改変髄膜炎菌fHBPポリペプチド
|
WO2011084705A2
(en)
|
2009-12-17 |
2011-07-14 |
Fina Biosolutions, Llc |
Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
EP2555794A4
(en)
|
2010-04-05 |
2014-01-15 |
Univ Chicago |
PROTEIN A (SPA) ANTIBODY COMPOSITIONS AND METHODS AS AN IMMUNE RESPONSE AMPLIFIER
|
US8383783B2
(en)
|
2010-04-23 |
2013-02-26 |
Serum Institute Of India, Ltd. |
Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels
|
JP6002128B2
(ja)
|
2010-07-02 |
2016-10-05 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
プロテインA(SpA)変種に関連する組成物および方法
|
JP5793194B2
(ja)
|
2010-09-09 |
2015-10-14 |
ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago |
感染防御ブドウ球菌抗原が関与する方法および組成物
|
GB201106225D0
(en)
|
2011-04-13 |
2011-05-25 |
Glaxosmithkline Biolog Sa |
Fermentation process
|
US8945588B2
(en)
|
2011-05-06 |
2015-02-03 |
The University Of Chicago |
Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
|
AU2012335208B2
(en)
|
2011-11-07 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
AU2013252883B2
(en)
|
2012-04-26 |
2018-05-17 |
University Of Chicago |
Staphylococcal coagulase antigens and methods of their use
|
US20150273036A1
(en)
|
2012-10-12 |
2015-10-01 |
Glaxosmithkline Biologicals Sa |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
JP2016501550A
(ja)
|
2012-12-27 |
2016-01-21 |
グリコヴァキシン アーゲー |
Crm197に関する方法及び組成物
|
US8916173B2
(en)
|
2013-03-08 |
2014-12-23 |
Crucell Holland B.V. |
Acellular pertussis vaccine
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
KR20180099912A
(ko)
|
2013-09-08 |
2018-09-05 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
MY194920A
(en)
*
|
2013-10-11 |
2022-12-23 |
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd |
Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
EP4286000A3
(en)
|
2014-01-21 |
2024-02-14 |
Pfizer Inc. |
Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CA3206112A1
(en)
|
2014-01-21 |
2015-07-30 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
DK3099800T3
(da)
|
2014-01-31 |
2021-01-11 |
Fina Biosolutions Llc |
Ekspression og oprensning af crm197 og beslægtede proteiner
|
US10392424B2
(en)
|
2014-02-28 |
2019-08-27 |
Glaxosmithkline Biologicals Sa |
Modified meningococcal fHbp polypeptides
|
EP2921856B1
(en)
|
2014-03-18 |
2016-09-14 |
Serum Institute Of India Private Limited |
A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
|
US9815886B2
(en)
|
2014-10-28 |
2017-11-14 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
EP3229833A1
(en)
|
2014-12-10 |
2017-10-18 |
GlaxoSmithKline Biologicals SA |
Method of treatment
|
EP3034516A1
(en)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification of streptococcal capsular polysaccharide
|
HRP20230416T1
(hr)
|
2015-01-15 |
2023-07-07 |
Pfizer Inc. |
Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
|
EP3270897A4
(en)
|
2015-03-20 |
2018-12-05 |
The Regents Of The University Of Michigan |
Immunogenic compositions for use in vaccination against bordetella
|
MX368897B
(es)
|
2015-05-04 |
2019-10-21 |
Pfizer |
Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos.
|
PL3313436T3
(pl)
|
2015-06-23 |
2021-06-14 |
Biological E Limited |
Wielowartościowa skoniugowana szczepionka przeciw pneumokokom
|
KR102225282B1
(ko)
|
2015-07-21 |
2021-03-10 |
화이자 인코포레이티드 |
접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2017085586A1
(en)
|
2015-11-20 |
2017-05-26 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
WO2017220753A1
(en)
|
2016-06-22 |
2017-12-28 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3269385A1
(en)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
CA3031797A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
EP3493837B1
(en)
|
2016-08-05 |
2022-08-31 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
AU2017321039B2
(en)
|
2016-09-02 |
2021-03-18 |
Glaxosmithkline Biologicals Sa |
Vaccines for Neisseria gonorrhoeae
|
BR112019004303A2
(pt)
*
|
2016-09-06 |
2019-05-28 |
Lg Chemical Ltd |
composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
|
CN109789198A
(zh)
|
2016-09-30 |
2019-05-21 |
生物E有限公司 |
包含多糖-蛋白缀合物的多价肺炎球菌疫苗组合物
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
EP3551668A1
(en)
|
2016-12-06 |
2019-10-16 |
GlaxoSmithKline Biologicals S.A. |
Purification process for capsular polysaccharide
|
MX2019008564A
(es)
|
2017-01-20 |
2019-09-19 |
Pfizer |
Composiciones inmunogenicas para su uso en vacunas neumococicas.
|
KR102650073B1
(ko)
|
2017-01-31 |
2024-03-20 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
|
BR112019014397A2
(pt)
|
2017-01-31 |
2020-02-11 |
Pfizer Inc. |
Composições de neisseria meningitidis e métodos das mesmas
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
BR112020004509A8
(pt)
|
2017-09-07 |
2023-01-31 |
Merck Sharp & Dohme |
Conjugado polissacarídeo-proteína carreadora, composição imunogênica compreendendo o mesmo e uso do referido conjugado
|
BR122021023687A8
(pt)
|
2017-12-06 |
2023-02-07 |
Merck Sharp & Dohme |
Usos de composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
CN112673054A
(zh)
|
2018-07-19 |
2021-04-16 |
葛兰素史密丝克莱恩生物有限公司 |
用于制备干燥多糖的方法
|
EP3607967A1
(en)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Modified meningococcal fhbp polypeptides
|
WO2020120569A2
(en)
|
2018-12-12 |
2020-06-18 |
Glaxosmithkline Biologicals Sa |
Modified carrier proteins for o-linked glycosylation
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
US20220296695A1
(en)
|
2018-12-19 |
2022-09-22 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
US20220118072A1
(en)
|
2019-02-11 |
2022-04-21 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
MX2021013736A
(es)
|
2019-05-10 |
2021-12-10 |
Glaxosmithkline Biologicals Sa |
Produccion de conjugados.
|
EP3757217A1
(en)
|
2019-06-27 |
2020-12-30 |
GlaxoSmithKline Biologicals S.A. |
Methods for protein purification
|
MX2022001241A
(es)
|
2019-07-31 |
2022-04-20 |
Sanofi Pasteur Inc |
Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
KR20220069992A
(ko)
|
2019-09-27 |
2022-05-27 |
화이자 인코포레이티드 |
네이세리아 메닌기티디스 조성물 및 그의 방법
|
EP3799884A1
(en)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
CN114728051A
(zh)
|
2019-11-22 |
2022-07-08 |
葛兰素史克生物有限公司 |
细菌糖糖缀合物疫苗的剂量和施用
|
IL295713A
(en)
|
2020-02-21 |
2022-10-01 |
Pfizer |
Isolation of saccharides
|
WO2021176409A1
(en)
|
2020-03-05 |
2021-09-10 |
Sanofi Healthcare India Private Limited |
Preservative combination for vaccine composition
|
EP3900739A1
(en)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
JP2023529925A
(ja)
|
2020-06-12 |
2023-07-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ナノ粒子ワクチンを使用する細菌免疫化
|
WO2021259742A1
(en)
|
2020-06-25 |
2021-12-30 |
Glaxosmithkline Biologicals Sa |
Modified exotoxin a proteins
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
WO2022043855A1
(en)
|
2020-08-26 |
2022-03-03 |
Pfizer Inc. |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
US20220088165A1
(en)
|
2020-09-17 |
2022-03-24 |
Janssen Pharmaceuticals, Inc. |
Multivalent vaccine compositions and uses thereof
|
US20230405104A1
(en)
|
2020-10-20 |
2023-12-21 |
Shanghai Reinovax Biologics Co., Ltd |
Proteoglycan conjugate and application thereof
|
US20230383324A1
(en)
|
2020-10-22 |
2023-11-30 |
Pfizer Inc. |
Methods for purifying bacterial polysaccharides
|
US20240000912A1
(en)
|
2020-11-04 |
2024-01-04 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
WO2023111826A1
(en)
|
2021-12-14 |
2023-06-22 |
Glaxosmithkline Biologicals Sa |
Bacterial immunization using qbeta hairpin nanoparticle constructs
|
WO2023118033A1
(en)
|
2021-12-22 |
2023-06-29 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
CN114965784B
(zh)
*
|
2022-06-01 |
2023-10-27 |
艾美探索者生命科学研发有限公司 |
多糖活化度的测定方法
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|